A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Public ClinicalTrials.gov record NCT03797261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Study identification
- NCT ID
- NCT03797261
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 9 participants
Conditions and interventions
Interventions
- Venetoclax Drug
- AMG 176 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2019
- Primary completion
- Dec 29, 2019
- Completion
- Dec 29, 2019
- Last update posted
- Dec 6, 2021
2019
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 207393 | Duarte | California | 91010 | — |
| USC Norris Cancer Center /ID# 207396 | Los Angeles | California | 90033 | — |
| University of Iowa Hospitals and Clinics /ID# 207459 | Iowa City | Iowa | 52242 | — |
| Univ Kansas Med Ctr /ID# 207480 | Kansas City | Kansas | 66160 | — |
| Duplicate_Dana-Farber Cancer Institute /ID# 207367 | Boston | Massachusetts | 02215 | — |
| Washington University-School of Medicine /ID# 206995 | St Louis | Missouri | 63110 | — |
| NYU Langone Medical Center /ID# 207390 | New York | New York | 10016-6402 | — |
| Unc /Id# 207388 | Chapel Hill | North Carolina | 27599 | — |
| UPMC Hillman Cancer Ctr /ID# 208482 | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03797261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2021 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03797261 live on ClinicalTrials.gov.